- Home
- ERII vs TNGX Comparison
ERII vs TNGX Comparison
Compare ERII & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERII
- TNGX
- Stock Information
- Founded
- ERII 1992
- TNGX 2014
- Country
- ERII United States
- TNGX United States
- Employees
- ERII N/A
- TNGX N/A
- Industry
- ERII Industrial Machinery/Components
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ERII Technology
- TNGX Health Care
- Exchange
- ERII Nasdaq
- TNGX Nasdaq
- Market Cap
- ERII 801.2M
- TNGX 723.2M
- IPO Year
- ERII 2008
- TNGX N/A
- Fundamental
- Price
- ERII $18.08
- TNGX $7.63
- Analyst Decision
- ERII Buy
- TNGX Strong Buy
- Analyst Count
- ERII 4
- TNGX 6
- Target Price
- ERII $18.75
- TNGX $10.80
- AVG Volume (30 Days)
- ERII 411.4K
- TNGX 3.9M
- Earning Date
- ERII 11-05-2025
- TNGX 11-06-2025
- Dividend Yield
- ERII N/A
- TNGX N/A
- EPS Growth
- ERII 25.10
- TNGX N/A
- EPS
- ERII 0.43
- TNGX N/A
- Revenue
- ERII $141,775,000.00
- TNGX $24,296,000.00
- Revenue This Year
- ERII $6.16
- TNGX $20.42
- Revenue Next Year
- ERII $13.06
- TNGX N/A
- P/E Ratio
- ERII $41.95
- TNGX N/A
- Revenue Growth
- ERII 6.19
- TNGX N/A
- 52 Week Low
- ERII $10.86
- TNGX $1.03
- 52 Week High
- ERII $20.27
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- ERII 84.33
- TNGX 45.65
- Support Level
- ERII $16.61
- TNGX $6.69
- Resistance Level
- ERII $15.79
- TNGX $9.39
- Average True Range (ATR)
- ERII 0.44
- TNGX 0.76
- MACD
- ERII 0.18
- TNGX -0.09
- Stochastic Oscillator
- ERII 92.66
- TNGX 32.06
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.